Abstract
Compounds with different sets of three of the four functional groups of (1R,2R,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-3-ene-1,2-diol 1 possessing high antiparkinsonian activity were synthesized. The synthesized compounds were tested for the antiparkinsonian activity in vivo on a mouse model with MPTP neurotoxin. A pronounced antiparkinsonian effect of 1 can only be achieved if it contains all the four functional groups (two hydroxy groups and two double bonds). The 2-hydroxy group or the 3,4-double bond is not required for stimulating the exploratory activity of the animals.
Keywords: Antiparkinsonian activity, functional groups, (1R, 2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1, 2-diol, mice, MPTP model.
Medicinal Chemistry
Title:3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity
Volume: 9 Issue: 5
Author(s): Oleg V. Ardashov, Alla V. Pavlova, Dina V. Korchagina, Konstantin P. Volcho, Tat’ yana G. Tolstikova and Nariman F. Salakhutdinov
Affiliation:
Keywords: Antiparkinsonian activity, functional groups, (1R, 2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1, 2-diol, mice, MPTP model.
Abstract: Compounds with different sets of three of the four functional groups of (1R,2R,6S)-3-methyl-6-(prop-1-en-2- yl)cyclohex-3-ene-1,2-diol 1 possessing high antiparkinsonian activity were synthesized. The synthesized compounds were tested for the antiparkinsonian activity in vivo on a mouse model with MPTP neurotoxin. A pronounced antiparkinsonian effect of 1 can only be achieved if it contains all the four functional groups (two hydroxy groups and two double bonds). The 2-hydroxy group or the 3,4-double bond is not required for stimulating the exploratory activity of the animals.
Export Options
About this article
Cite this article as:
Ardashov V. Oleg, Pavlova V. Alla, Korchagina V. Dina, Volcho P. Konstantin, Tolstikova G. Tat’ yana and Salakhutdinov F. Nariman, 3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity, Medicinal Chemistry 2013; 9 (5) . https://dx.doi.org/10.2174/1573406411309050013
DOI https://dx.doi.org/10.2174/1573406411309050013 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Current Medicinal Chemistry Adenosine and Related Drugs in Brain Diseases: Present and Future in Clinical Trials
Current Topics in Medicinal Chemistry Homocysteine and Hyperhomocysteinaemia
Current Medicinal Chemistry Antipsychotics and Cognitive Functioning: A Critical Review
Current Psychopharmacology Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Current Topics in Medicinal Chemistry The GABA Shunt: An Attractive and Potential Therapeutic Target in the Treatment of Epileptic Disorders
Current Drug Metabolism Biomarkers in the Exhaled Breath Condensate of Healthy Adults: Mapping the Path Towards Reference Values
Current Medicinal Chemistry Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Current Drug Targets Update on the Adverse Effects of Clozapine: Focus on Myocarditis
Current Drug Safety The Rabbit Syndrome: State of the Art
Current Clinical Pharmacology Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Advances in the Physiology of GPR55 in the Central Nervous System
Current Neuropharmacology Efficacy and Adverse Effects of Venlafaxine in Children and Adolescents with ADHD: A Systematic Review of Non-controlled and Controlled Trials
Reviews on Recent Clinical Trials Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs
CNS & Neurological Disorders - Drug Targets Current Status of Antipsychotic Treatment
Current Drug Targets - CNS & Neurological Disorders